Get the Stockscreener App
17.39
2.90%
-0.52
After Hours:
17.35
-0.04
-0.23%
Sarepta Therapeutics Inc stock is traded at $17.39, with a volume of 3.48M.
It is down -2.90% in the last 24 hours and down -7.50% over the past month.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
See More
Previous Close:
$17.91
Open:
$17.97
24h Volume:
3.48M
Relative Volume:
0.29
Market Cap:
$1.70B
Revenue:
$2.23B
Net Income/Loss:
$-248.39M
P/E Ratio:
-6.4647
EPS:
-2.69
Net Cash Flow:
$-697.55M
1W Performance:
-7.06%
1M Performance:
-7.50%
6M Performance:
-82.57%
1Y Performance:
-86.13%
1-Day Range:
$17.23
$18.21
1-Week Range:
$16.85
$18.77
52-Week Range:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.39 | 1.80B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Scientech Research LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of "Hold" from Analysts - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Sarepta Therapeutics Shares - GuruFocus
Leerink Partnrs Has Positive Forecast for SRPT Q3 Earnings - MarketBeat
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Published on: 2025-09-12 04:51:21 - Newser
Responsive Playbooks and the SRPT Inflection - news.stocktradersdaily.com
(SRPT) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Ranking Sarepta Therapeutics Inc. among high performing stocks via toolsTrade Entry Report & Short-Term Trading Opportunity Alerts - Newser
Investigation announced for Long-Term Investors in Sarepta - openPR.com
Sarepta Therapeutics Inc. stock outlook for YEAR2025 Big Picture & Precise Entry and Exit Recommendations - Newser
Price-Driven Insight from (SRPT) for Rule-Based Strategy - news.stocktradersdaily.com
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Behavioral Patterns of SRPT and Institutional Flows - news.stocktradersdaily.com
Understanding Momentum Shifts in (SRPT) - news.stocktradersdaily.com
Understanding the Setup: (SRPT) and Scalable Risk - news.stocktradersdaily.com
(SRPT) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
(SRPT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
(SRPT) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
The Technical Signals Behind (SRPT) That Institutions Follow - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Connect - ACCESS Newswire
Liquidity Mapping Around (SRPT) Price Events - news.stocktradersdaily.com
Is Century Therapeutics Inc. stock undervalued right nowFed Meeting & AI Based Buy and Sell Signals - Lancaster City Council
(SRPT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Eventide Asset Management LLC Sells 58,580 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
(SRPT) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
How (SRPT) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
(SRPT) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Discipline and Rules-Based Execution in SRPT Response - news.stocktradersdaily.com
Why (SRPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
5 Companies Caught on a Carousel of FDA Confusion - BioSpace
Trading Systems Reacting to (SRPT) Volatility - news.stocktradersdaily.com
ADAR1 Capital Management LLC Raises Holdings in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Vestal Point Capital LP - MarketBeat
Does Sarepta Therapeutics Inc. fit your quant trading modelWeekly Trend Report & Fast Entry High Yield Tips - Newser
What recovery options are there for Sarepta Therapeutics Inc.Quarterly Profit Report & Daily Market Momentum Tracking - Newser
Braidwell LP Trims Stake in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Navigating the Legal Quicksand: Securities Litigation Risks and Investor Protection in Biotech Stocks - AInvest
SEC Filings Archive 2025-09-05Historical 10-K, 10-Q, 8-K Forms - Stock Titan
Avoiding Lag: Real-Time Signals in (SRPT) Movement - news.stocktradersdaily.com
Should value investors consider Sarepta Therapeutics Inc.2025 Biggest Moves & Risk Managed Investment Strategies - خودرو بانک
2 Beaten-Down Stocks to Avoid Right Now - The Motley Fool
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year - Yahoo Finance
Long term hold vs stop loss in Sarepta Therapeutics Inc.Weekly Risk Summary & Short-Term Swing Trade Alerts - Newser
When is the best time to buy Sarepta Therapeutics Inc. stockShare Buyback & Real-Time Buy Signal Notifications - Newser
Is Sarepta Therapeutics Inc. reversing from oversold territoryJuly 2025 Rallies & Free Safe Entry Trade Signal Reports - Newser
Is Sarepta Therapeutics Inc. stock heavily shortedJuly 2025 Drop Watch & Consistent Profit Focused Trading Strategies - خودرو بانک
Sarepta Therapeutics Inc. stock prediction for this weekQuarterly Earnings Report & Verified Trade Idea Suggestions - Newser
Can Sarepta Therapeutics Inc. deliver consistent EPS growthJuly 2025 Closing Moves & Short-Term High Return Ideas - خودرو بانک
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):